Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Phase 1 save search
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
Published: 2023-03-23 (Crawled : 12:20) - biospace.com/
ENVB | $0.938 4.52% 4.33% 180K
|
Health Technology
|
| O: 2.56%
H: 0.04%
C: -5.0%
eb-373 study phase 1
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | News | $0.4634 -5.24% -5.52% 280K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
trial therapeutics plus phase 1
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
FUSN | $21.4 -0.09% -0.09% 270K
|
Health Technology
|
| O: -2.17%
H: 3.69%
C: -1.48%
fpi-2059 tumors treatment pharmaceuticals therapy study phase 1
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.445 -1.22% -1.24% 230K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
prtx007 research meeting association therapeutics cancer study phase 1
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Published: 2023-03-08 (Crawled : 19:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K
|
Health Technology
|
| O: 2.12%
H: 2.52%
C: -5.6%
ph10 spray trial phase 1 major depressive disorder
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3252 15.67% 20K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
DYAI 4 | $1.52 2.01% 1.97% 3.4K
|
Health Technology
|
| O: -0.71%
H: 21.43%
C: 20.71%
dyai-100 covid-19 candidate protein vaccine trial update phase 1
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
CELZ | $4.8201 0.21% 8.8K
|
|
| O: 1.56%
H: 0.0%
C: -6.18%
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.03%
H: 0.45%
C: -1.01%
celz-201 medical technology trial diabetes international phase 1
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.46%
H: 2.06%
C: -0.46%
treatment ongoing study phase 1
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Published: 2023-02-27 (Crawled : 23:00) - globenewswire.com
OCGN | News 4 | $1.17 -6.4% -6.84% 7.3M
|
Health Technology
|
| O: -0.06%
H: 5.6%
C: 2.13%
ocu200 treatment fda drug macular application trial submission diabetic phase 1
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
CDXS | $2.82 -2.76% -2.84% 210K
|
Process Industries
|
| O: -1.82%
H: 0.0%
C: -12.24%
cdx-7108 health trial pancreatic exocrine pancreatic insufficiency phase 1
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Published: 2023-02-22 (Crawled : 15:00) - biospace.com/
DARE | $0.2843 -4.37% -4.57% 400K
|
Health Technology
|
| O: 0.93%
H: 4.59%
C: -1.83%
treatment potential bioscience study phase 1
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
IMCR | $58.52 2.11% 2.07% 390K
|
Manufacturing
|
| O: -1.52%
H: 2.86%
C: -0.17%
hiv therapy living phase 1
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 4.49%
H: 0.0%
C: -16.41%
bpx-601 symposium asco cancer prostate cancer phase 1
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: -0.31%
H: 8.62%
C: -1.88%
bn301 treatment china study phase 1
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Published: 2023-02-11 (Crawled : 16:20) - globenewswire.com
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
| Email alert
Add to watchlist
treatment ongoing ocular trial phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.